MNPR
NASDAQ
$105.90
Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $113.62 (+7.29%)
Market Cap
$728M
Free Cash Flow Yield
-1.38%
Beta (5Y)
1.67
Price Chart
Valuation
Market Cap$728M
P/B4.94
Profitability
EBITDA-$15M
EPS-$2.27
Financial Health
Free Cash Flow Yield-1.38%
Growth & Risk
EPS 5Y CAGR-5.81%
FCF 5Y CAGR+12.83%
Beta (5Y)1.67
Sharpe Ratio1.38